• 19 August 2016

    August 19, 2016 – The Board of InDex Pharmaceuticals today announced its intention to proceed with an Initial Public Offering of the drug development company on Nasdaq First North during the autumn. A new share issue in order to raise capital for the development of the company’s lead drug candidate – cobitolimod – is planned in connection with the listing.

  • 15 August 2016

    Wilson Therapeutics AB (publ), announces the appointment of Vincent Metzler as Vice President Commercial Planning & Launch Strategy. Dr Metzler will report to CEO Jonas Hansson and will join the company’s management team.

  • 28 July 2016

    Irvine, CA, July 28, 2016 – Axonics® Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that it has received magnetic resonance imaging (MRI) conditional labeling approval in Europe for its SNM System. Patients receiving implants of the Axonics SNM System are now able to safely undergo head and neck MRI scans in 1.5 Tesla and 3 Tesla environments.

  • 25 July 2016

    LAGUNA HILLS, Calif., July 25, 2016 – /Globe Newswire/ — Sonendo®, Inc., — The developer of a breakthrough technology that offers an alternative to conventional root canal therapy, today announced that clinical results using their GentleWave® System have been reported in the current print and online issues of the Journal of Endodontics. The study can be found online at                                                                                          

  • 11 July 2016

    Zurich, SWITZERLAND – 11 July 2016 – Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, heart disease and certain cancers, announced today the appointment of Ian Crosbie as Chief Financial Officer.